Akoya Biosciences, Inc.

NasdaqGS:AKYA Voorraadrapport

Marktkapitalisatie: US$104.6m

Akoya Biosciences Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Akoya Biosciences de winst en omzet met respectievelijk 28.8% en 8.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 33% per jaar.

Belangrijke informatie

28.8%

Groei van de winst

33.0%

Groei van de winst per aandeel

Life Sciences winstgroei18.4%
Inkomstengroei8.9%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt25 Nov 2024

Recente toekomstige groei-updates

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Winst- en omzetgroeiprognoses

NasdaqGS:AKYA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026106-24-17-67
12/31/202592-32-16-98
12/31/202482-56-43-438
9/30/202487-58-49-47N/A
6/30/202493-60-54-51N/A
3/31/202494-68-56-52N/A
12/31/202397-63-55-51N/A
9/30/202391-71-59-55N/A
6/30/202385-76-61-54N/A
3/31/202379-73-62-55N/A
12/31/202275-71-61-53N/A
9/30/202270-69-57-49N/A
6/30/202264-63-57-51N/A
3/31/202260-51-55-50N/A
12/31/202155-44-41-36N/A
9/30/202152-34-37-32N/A
6/30/202148-28-24-21N/A
3/31/202144-28-13-10N/A
12/31/202042-22-10-7N/A
12/31/201942-18-17-14N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat AKYA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat AKYA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat AKYA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van AKYA ( 8.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van AKYA ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van AKYA naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven